Integra EVP granted 92,108 RSUs, tax shares withheld

INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & President, CSS, received a grant of 92,108 restricted stock units that will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.

Rhea-AI Filing Summary

INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael J. McBreen, EVP & President, CSS, received a grant of 92,108 restricted stock units that will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.

To cover tax obligations, he disposed of 2,354 and 7,247 shares of common stock at $9.55 and $9.61 per share through tax-withholding transactions, not open-market sales. Following these transactions, he directly holds 60,743 common shares and the new 92,108 RSUs.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider McBreen Michael J.

Role EVP & President, CSS

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	92,108	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	7,247	$9.61	$70K
Exercise Price or Tax Liability	Common Stock	2,354	$9.55	$22K

Holdings After Transaction: Restricted Stock Units — 92,108 contracts (Direct); Common Stock — 60,743 shares (Direct)

Footnotes (1)

1. F1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Integra LifeSciences (IART) report in this Form 4 for Michael McBreen?

Integra LifeSciences reported that EVP & President, CSS Michael J. McBreen received a grant of 92,108 restricted stock units and had shares withheld in two transactions to satisfy tax obligations linked to his equity compensation awards.

How many restricted stock units did IART grant to executive Michael McBreen?

Michael McBreen was granted 92,108 restricted stock units tied to Integra LifeSciences common stock. These RSUs vest over three years, with 33% vesting on the first and second anniversaries and 34% vesting on the third anniversary of the March 11, 2026 grant date.

What does the Form 4 say about Michael McBreen’s current IART share holdings?

After the reported transactions, Michael McBreen directly holds 60,743 shares of Integra LifeSciences common stock. In addition, he holds 92,108 restricted stock units that will convert into shares as they vest over the three-year schedule described in the compensation award footnote.

How will Michael McBreen’s new IART restricted stock units vest over time?

The 92,108 restricted stock units vest in three tranches: 33% on the first anniversary of the March 11, 2026 grant date, another 33% on the second anniversary, and the remaining 34% on the third anniversary, subject to the award’s standard vesting conditions.

What do the F-code transactions mean in this IART Form 4 filing?

The F-code entries show 2,354 and 7,247 common shares were disposed of to pay tax liabilities by delivering shares. These are tax-withholding dispositions at $9.55 and $9.61 per share, not open-market sales, and are typical for equity compensation vesting events.

Did Michael McBreen buy or sell IART shares on the open market?

The filing does not show any open-market purchases or sales. It reports a grant of 92,108 restricted stock units and two F-code tax-withholding dispositions, where shares were surrendered to cover taxes rather than being sold in ordinary market transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 05:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McBreen Michael J.

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & President, CSS

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		F		2,354	D	$9.55	67,990	D
Common Stock	03/11/2026		F		7,247	D	$9.61	60,743	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		92,108		(1)	(1)	Common Stock	92,108	$0	92,108	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date of 3/11/2026.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Michael J. McBreen	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.